KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EBIT: 2010-2024

Historic EBIT for TherapeuticsMD (TXMD) over the last 15 years, with Dec 2024 value amounting to -$4.8 million.

  • TherapeuticsMD's EBIT rose 23.99% to -$862,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year increase of 74.12%. This contributed to the annual value of -$4.8 million for FY2024, which is 44.15% up from last year.
  • Per TherapeuticsMD's latest filing, its EBIT stood at -$4.8 million for FY2024, which was up 44.15% from -$8.5 million recorded in FY2023.
  • In the past 5 years, TherapeuticsMD's EBIT registered a high of $1.2 million during FY2022, and its lowest value of -$155.5 million during FY2020.
  • In the last 3 years, TherapeuticsMD's EBIT had a median value of -$4.8 million in 2024 and averaged -$4.0 million.
  • As far as peak fluctuations go, TherapeuticsMD's EBIT soared by 101.50% in 2022, and later crashed by 815.62% in 2023.
  • Over the past 5 years, TherapeuticsMD's EBIT (Yearly) stood at -$155.5 million in 2020, then surged by 48.84% to -$79.6 million in 2021, then spiked by 101.50% to $1.2 million in 2022, then plummeted by 815.62% to -$8.5 million in 2023, then spiked by 44.15% to -$4.8 million in 2024.